To understand if T-cell subtypes may exhibit clonal expansion that is missed in bulk PBMC analyses, we used sorted CD4+ and CD8+ PBMC obtained before, during and after ICB as first-line therapy for HL. This evidence concerns the gene CD8A and Hodgkins lymphoma.